PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
47.13%
Some net income increase while AXSM is negative at -114.90%. John Neff would see a short-term edge over the struggling competitor.
3.87%
Less D&A growth vs. AXSM's 29.71%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
17.23%
Lower deferred tax growth vs. AXSM's 1465.11%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
-49.98%
Negative yoy SBC while AXSM is 94.56%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
93.54%
Slight usage while AXSM is negative at -25.09%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.23%
A yoy AP increase while AXSM is negative at -97.40%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
21.18%
Lower 'other working capital' growth vs. AXSM's 257.49%. David Dodd would see fewer unexpected short-term demands on cash.
-49.98%
Negative yoy while AXSM is 32.52%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
33.57%
Operating cash flow growth above 1.5x AXSM's 8.75%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-2609.70%
Both yoy lines negative, with AXSM at -210.35%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2609.70%
Both yoy lines negative, with AXSM at -210.35%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
5.36%
Debt repayment well below AXSM's 98.58%. Michael Burry suspects heavier leverage risk or insufficient cash generation to keep pace.
-80.40%
Negative yoy issuance while AXSM is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.